Bluejay Diagnostics
BJDX
0 hedge funds and large institutions have $55.7K invested in Bluejay Diagnostics in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0.83% less ownership
Funds ownership: 1.5% → 0.67% (-0.83%)
100% less funds holding
Funds holding: 2 → 0 (-2)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $126K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$70.9K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.5K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$9.9K |
| 4 |
Two Sigma Securities
New York
|
-$6.78K |
| 5 |
StoneX Group
New York
|
-$5.7K |
BJDX Hedge Fund Activity: Q1 2023 in Review
0 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Bluejay Diagnostics (BJDX) for Q1 2023, worth a combined $55.7K — down 49% from $109K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BJDX and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $70.9K sold.
- 0 institutional investors held Bluejay Diagnostics (BJDX) as of Q1 2023, down from 2 in Q4 2022.
- Funds reported $55.7K of Bluejay Diagnostics stock for Q1 2023, down 49% quarter-over-quarter.
- 0 funds opened new Bluejay Diagnostics positions in Q1 2023 and 2 closed out, a net change of -2 holders.
- The largest Bluejay Diagnostics seller in Q1 2023 was Renaissance Technologies, an estimated $70.9K sold.
Based on aggregated 13F filings for Q1 2023.